Biosimilars already approved and in development-Reference-Cited by-同舟云学术

Biosimilars already approved and in development

Published:2017-10-01 Issue:1 Volume:1 Page:7-12
ISSN:2515-3919
Container-title:Considerations in Medicine
language:en
Short-container-title:Considerations Med

Author:

Dörner Thomas,Isaacs John,Gonçalves João,Azevedo Valderilio,Castañeda-Hernández Gilberto,Strohal Robert,McInnes Iain

Publisher

BMJ

Subject

Electrical and Electronic Engineering,Atomic and Molecular Physics, and Optics

Reference27 articles.

2. QuintilesIMS. The impact of biosimilar competition in Europe. London: QuintilesIMS, 2017. www.medicinesforeurope.com/wp-content/uploads/./IMS-Biosimilar-2017_V9.pdf

3. The changing landscape of biosimilars in rheumatology

4. Genericsand Biosimilars Initiative (GaBI).http://www.gabionline.net/.

5. Sandoz. Sandoz biosimilar pipeline. https://www.sandoz.com/our-work/biopharmaceuticals/sandoz-biosimilar-pipeline

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilars in der Kinderrheumatologie;Kinder- und Jugendmedizin;2021-10

2. A Checklist for Pharmacists on Biologics and Biosimilars;Biologics, Biosimilars, and Biobetters;2020-12-30

3. A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis;Rheumatology and Therapy;2019-12-12

4. Effects of Soluble Tumor Necrosis Factor (TNF) on Antibody-Dependent Cellular Cytotoxicity of Therapeutic anti-TNF-α Antibody;Immunological Investigations;2018-12-20

5. Biosimilars: considerations for clinical practice;Considerations in Medicine;2017-10-01